Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Direvo appoints new members to the supervisory board


Cologne, Germany, October 25, 2007 – DIREVO Biotech AG, a leading company for superior bioengineered products and processes for industrial and pharmaceutical applications, announced today the appointment of four new supervisory board members following the successful closing of a series C financing of €12 million. The new members of the board are:

Dr. Simon G. Best
Dr. Best is co-founder and Chairman of Ardana Plc (Edinburgh, UK) and was founding CEO of Roslin Bio-Med (Midlothian, UK), acquired by Geron Corporation in 1999. He is also Chairman of the UK BioIndustry Association (BIA).

James C. Gale
Mr. Gale is Managing Director at Signet Healthcare Partners, an affiliate of Sanders Morris Harris (New York, USA), of which he is Founding Partner.

Dr. Leif Kjærgaard
Dr. Kjærgaard is Chief Technology Officer for Technology and Business Development, Danisco A/S (Copenhagen, Denmark).

Prof. Dr. Detlev H. Riesner
Prof. Riesner is Co-Founder and Chairman of the Supervisory Board of Qiagen (Hilden, Germany) and Chairman emeritus of the Biophysiscs Department at the Heinrich-Heine-University of Düsseldorf (Dusseldorf, Germany).

The newly appointed Members of the Board replace Nobel Laureate Prof. Dr. Manfred Eigen (2000-2007), Prof. Dr. Peter Donner (2001 – 2007), Dr. Rüdiger Hauffe (2001 – 2007) and Prof. Dr. Bernd Wetzel (2003 – 2007).

Dr. Hubert Birner (Chairman) and Prof. Heinrich Schulte (Vice Chairman) will continue to serve as board members and have been members of the Supervisory Board of Direvo since 2000 and 2006 respectively.

”We are delighted to have such a high calibre Board which brings together an enormous amount of expertise in all areas relevant to Direvo “, stated Dr. Thomas von Rüden, CEO of Direvo.

Dr. Hubert Birner, Chairman of the Supervisory Board added: “I would like to thank the departing Members of the Supervisory Board for their commitment to Direvo and their invaluable contributions to the company's development.”

- end -

Direvo Biotech AG

DIREVO Biotech AG generates superior bioengineered products and processes for industrial and pharmaceutical markets by enhancing nature's potential. The Company’s portfolio includes optimized proteins, optimized bioprocesses and other bio-molecules, in research, in commercial development and on the market. Direvo develops products both independently and with global leaders such as Danisco/Genencor, Nestlé and an undisclosed “top five” Pharma partner. Direvo Biotech is committed to a tailored approach to addressing customer needs and market opportunities.

Direvo’s industrial biotechnology business focuses on food & feed, and biorefinery markets. The Company provides solutions through discovery, development and scale up of enzymes, other molecules and strains. Industrial biotechnology at Direvo emphasizes environmental sustainability and the use of renewable resources. For example, a collaboration with Danisco A/S yielded a significantly improved enzyme that has reached the market as part of a Danisco/Genencor product.

Direvo’s biopharmaceuticals business focuses on therapeutic antibodies and proteases. Applying its powerful and proven protein engineering capabilities, Direvo generates improved second generation therapeutics and discovers and optimizes novel first-generation therapeutics. Direvo offers early stage partnering from internal discovery programs as well as collaborations on the optimization of a wide range of therapeutic proteins.

DIREVO Biotech AG is privately held and located in Cologne, Germany. Additional information is available at: www.direvo.com

Media contact:

DIREVO Biotech AG
Dr Thomas von Rüden, CEO
Tel. + 49 (0)221 8887-120
info@direvo.com


Publisher Contact Information:

Direvo
+ 49 (0)221 8887-120
info@direvo.com

Company profile of Direvo (acquired by Bayer HealthCare)
Past press releases of Direvo (acquired by Bayer HealthCare).

Data


27,722
Tech investments
From our Online Data Service
17,881
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Sep 30
TetaVi
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.